Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component
- 32 Downloads
Lung adenocarcinoma with the micropapillary (MP) component poses a higher risk of recurrence even when the MP component is not predominant. This study explored genetic features associated with highly malignant behavior of lung adenocarcinoma with the MP component.
The MP and papillary (PaP) components were captured separately in three patients. Comprehensive mRNA expressions of somatic variants were compared between the MP and PaP components of each patient using next-generation sequencing (NGS). The protein expression of the NGS-detected variant was validated by immunohistochemistry. The prognostic impact of the detected variant was evaluated in 288 adenocarcinoma patients with resection of pN0M0.
In two cases, NGS suggested higher RNA expression of EGFR L858R in the MP component than in the PaP component (allele frequency, 0.485 vs. 0.155 and 1.000 vs. 0.526, respectively; P < 0.001 for both). Immunohistochemistry validated intense expression of L858R in the MP component of 27 MP-positive (MP+) patients. Among 288 pN0M0 patients, L858R was more frequently harbored in the MP+ patients than in the MP-negative (MP−) patients. The MP+ patients harboring L858R showed significantly worse recurrence-free survival (RFS) than the MP+ patients without L858R (median RFS 38.7 and 55.0 months, respectively; hazard ratio [HR] 3.004; 95% confidence interval [CI] 1.306–9.132; P = 0.012). Multivariate analysis of the MP+ patients showed that positive L858R status was associated with poorer RFS (HR 2.976; 95% CI 1.190–7.442; P = 0.020).
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP− adenocarcinoma patients. Intense expression of L858R in the MP component was suggested, and the MP+ patients harboring L858R were at comparatively higher risk of recurrence in the group with pN0M0 lung adenocarcinoma.
This study was conducted in part at the Analysis Center of Life Science, Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan. The authors thank Editage (www.editage.jp) for English language editing.
There are no conflicts of interest.
- 1.Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85. https://doi.org/10.1097/jto.0b013e318206a221.CrossRefGoogle Scholar
- 2.Hung JJ, Yeh YC, Jeng WJ, et al. Predictive value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol. 2014;32:2357–64. https://doi.org/10.1200/jco.2013.50.1049.CrossRefPubMedGoogle Scholar
- 3.Mansuet-Lupo A, Bobbio A, Blons H, et al. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest. 2014;146:633–43. https://doi.org/10.1378/chest.13-2499.CrossRefPubMedGoogle Scholar
- 7.Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol. 2014;12:148. https://doi.org/10.1186/1477-7819-12-148.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30:1438–46. https://doi.org/10.1200/jco.2011.37.2185.CrossRefPubMedGoogle Scholar
- 12.Hung JJ, Jeng WJ, Wu YC, Chou TY, Hsu WH. Factors predicting organ-specific distant metastasis in patients with completely resected lung adenocarcinoma. Oncotarget. 2016;7:58261–73. https://doi.org/10.18632/oncotarget.11338.
- 18.Tsutsumida H, Nomoto M, Goto M, et al. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol. 2007;20:638–47. https://doi.org/10.1038/modpathol.3800780.CrossRefPubMedGoogle Scholar
- 21.Makimoto Y, Nabeshima K, Iwasaki H, et al. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤ 20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi’s type C tumours). Histopathology. 2005;46:677–84. https://doi.org/10.1111/j.1365-2559.2005.02126.x.CrossRefPubMedGoogle Scholar
- 23.GATK. Retrieved 31 Mar 2018. https://software.broadinstitute.org/gatk/.
- 24.SnpEff. Retrieved 31 Mar 2018. http://snpeff.sourceforge.net/.
- 25.COSMIC. Retrieved 31 Mar 2018. https://cancer.sanger.ac.uk/cosmic.
- 26.Travis WD, Brambilla E, Nicholson AG, et al. WHO Panel. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60. https://doi.org/10.1097/JTO.0000000000000630.CrossRefPubMedGoogle Scholar
- 27.Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009.CrossRefPubMedGoogle Scholar
- 28.Nagai Y, Miyazawa H, Tanaka T, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system: the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005;65:7276–82. https://doi.org/10.1158/0008-5472.CAN-05-0331.CrossRefPubMedGoogle Scholar
- 30.Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and genetics: tumours of the lung, pleura, thymus, and Heart. IARC Press, Lyon, 2004.Google Scholar
- 31.Zhang J, Sun J, Zhang Z, et al. Protein overexpression and gene amplification of cellular mesenchymal-epithelial transition factor is associated with poor prognosis in micropapillary-predominant subtype pulmonary adenocarcinoma. Hum Pathol. 2018;72:59–65. https://doi.org/10.1016/j.humpath.2017.10.031.CrossRefPubMedGoogle Scholar
- 34.Suda K, Murakami I, Yu H, et al. Heterogeneity of EGFR aberrations and correlation with histological structures: analyses of therapy-naive isogenic lung cancer lesions with EGFR mutation. J Thorac Oncol. 2016;11:1711–7. https://doi.org/10.1016/j.jtho.2016.05.017.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations, and gene expression analysis. Am J Surg Pathol. 2008;32:810–27. https://doi.org/10.1097/pas.0b013e31815cb162.CrossRefPubMedGoogle Scholar
- 39.Takenaka T, Takenoyama M, Yamaguchi M, et al. Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small cell lung cancer. Eur J Cardiothorac Surg. 2015;47:550–5. https://doi.org/10.1093/ejcts/ezu227.CrossRefPubMedGoogle Scholar